Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma.

Autor:	Steiner RE; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX., Hwang SR; Division of Hematology, Mayo Clinic Comprehensive Cancer Center, Rochester, MN., Khurana A; Division of Hematology, Mayo Clinic Comprehensive Cancer Center, Rochester, MN., Habermann TM; Division of Hematology, Mayo Clinic Comprehensive Cancer Center, Rochester, MN., Epperla N; The Ohio State University James Cancer Hospital and Solove Research Institute, Columbus, OH., Annunzio K; The Ohio State University James Cancer Hospital and Solove Research Institute, Columbus, OH., Allen PB; Winship Cancer Institute at Emory University, Atlanta, GA., Baird K; Winship Cancer Institute at Emory University, Atlanta, GA., Paulino D; Winship Cancer Institute at Emory University, Atlanta, GA., Alderuccio JP; Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL., Lossos IS; Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL., David K; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ., Evens AM; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ., Pandya K; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ., Bair SM; University of Colorado Anschutz Medical Campus, Aurora, CO., Kamdar M; University of Colorado Anschutz Medical Campus, Aurora, CO., Ba Aqeel S; Roswell Park Comprehensive Cancer Center, Buffalo, NY., Torka P; Roswell Park Comprehensive Cancer Center, Buffalo, NY., Lynch R; University of Washington Fred Hutchinson Cancer Research Center, Seattle, WA., Smith S; University of Washington Fred Hutchinson Cancer Research Center, Seattle, WA., Feng L; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX., Noorani M; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX., Ahmed S; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX., Nair R; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX., Vega F; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX., Wu S; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX., Fang P; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX., Pinnix CC; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX., Gunther JR; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX., Dabaja BS; Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX., Lee HJ; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX.
Jazyk:	angličtina
Zdroj:	Blood advances [Blood Adv] 2023 Dec 26; Vol. 7 (24), pp. 7485-7493.
DOI:	10.1182/bloodadvances.2023010700
Abstrakt:	In the pivotal study ECHELON-1, brentuximab vedotin (BV), doxorubicin, vinblastine, and dacarbazine (A + AVD) demonstrated superior efficacy compared with bleomycin + AVD for the treatment of advanced-stage classic Hodgkin lymphoma (cHL). However, there are minimal available data regarding the frequency of dose reductions or omission of BV during curative therapy and the potential impact on patient outcomes. In a real-world analysis, we retrospectively reviewed the characteristics and outcomes of 179 patients with stage III or IV cHL treated with frontline A + AVD from January 2010 to April 2022. Treatment consisted of up to 1.2 mg/kg of BV and standard dose AVD IV on days 1 and 15 of each 28-day cycle for up to 6 cycles. At the time of treatment, the median patient age was 37 years, and a high-risk International Prognostic Score was observed in 46% of patients. Overall, 91% of patients received 6 cycles of AVD; 55% of patients did not receive the intended cumulative dose of BV (CDB); 28% of patients received two-thirds or less than the planned CDB. At a median follow-up time of 27.4 months (95% confidence interval [CI], 24.8-29), the median progression-free survival (PFS) was not reached, and the 12-month PFS was 90.3% (95% CI, 85.9-95.0). The impact of CDB on PFS was not significant (P = .15), nor was high CDB significantly associated with increased adverse events. In real-world experience, A + AVD is a highly effective treatment for patients with advanced-stage cHL, including for patients with prominent dose reductions of BV. (© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu